Interestingly, the MM cell lines CAG and URVIN, harboring PIK3CA and PIK3R3 mutations, respectively, exhibited the highest sensitivity to taselisib and temsirolimus treatment, while JJN3, harboring mutations in PIK3CA and mTOR genes, showed less sensitivity to taselisib compared to CAG and URVIN cell lines. This evidence concerns the gene MTOR and Miyoshi myopathy.